GC Biopharma

GC Biopharma is a leading global biopharmaceutical company dedicated to improving lives through innovative solutions. With over 55 years of experience, the company specializes in developing and manufacturing plasma derivatives, vaccines, and therapies for rare diseases, alongside offering comprehensive Contract Manufacturing Organization (CMO) services. As a dominant leader in the Korean plasma derivatives market, GC Biopharma provides a range of high-quality plasma-derived products, ensuring the highest safety and efficacy standards. The company is also pioneering in vaccine development, with a broad portfolio that includes vaccines for influenza, varicella, hepatitis B, and hemorrhagic fever. Committed to addressing unmet medical needs, GC Biopharma develops innovative therapies for rare diseases such as Hunter syndrome and hemophilia, thereby improving the quality of life for patients worldwide. Their premium Fill & Finish services cater to clinical and commercial customers, utilising state-of-the-art facilities for vials and pre-filled syringes while ensuring excellent quality and compliance with global standards.

Services include:
- Aseptic Fill/Finish
- Biologics
- Bioprocessing
- Disposable/Single-Use
- Biosimilars
- Filling
- Syringe
- Vials
- Manufacturing
- Dose Form
- Sterile
- Injectables
- Lyophilization
- Pre-filled
- Vaccines
- Packaging
- Glass
- Quality QA/QC
- Stability Studies
- Sterility Testing
- Anatomical Therapeutic Chemical (ATC) Classification
- Contract Development and Manufacturing (CDMO)

GC Biopharma remains steadfast in its commitment to delivering innovative biopharmaceutical solutions that meet the evolving needs of the healthcare industry. For more information, please visit globalgreencross.com.